Overview
- Ipsen, which announced the results Thursday, said Dysport produced a statistically significant reduction in monthly migraine days versus placebo in both episodic and chronic migraine.
- The company described the findings as preliminary and has not released numeric results or full safety and subgroup data.
- Ipsen plans to present complete trial data at an upcoming scientific congress, where independent experts can review the results.
- Shares of Ipsen rose slightly in early Paris trading after the announcement, and a positive Phase 3 outcome could help offset revenue pressure from generics hitting its Somatuline franchise.
- Dysport is already used in aesthetic and neuromuscular treatments, so if regulators and clinicians confirm the data the drug could become the first botulinum toxin option specifically for migraine patients.